A detailed history of Veriti Management LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Veriti Management LLC holds 1,895 shares of ALNY stock, worth $480,837. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,895
Previous 2,942 35.59%
Holding current value
$480,837
Previous $714,000 27.03%
% of portfolio
0.03%
Previous 0.04%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$233.81 - $287.01 $244,799 - $300,499
-1,047 Reduced 35.59%
1,895 $521,000
Q2 2024

Aug 02, 2024

BUY
$143.31 - $247.0 $40,986 - $70,642
286 Added 10.77%
2,942 $714,000
Q1 2024

Apr 19, 2024

SELL
$146.51 - $198.2 $35,455 - $47,964
-242 Reduced 8.35%
2,656 $396,000
Q4 2023

Feb 05, 2024

BUY
$151.41 - $196.57 $51,479 - $66,833
340 Added 13.29%
2,898 $554,000
Q3 2023

Oct 27, 2023

BUY
$170.77 - $211.65 $31,933 - $39,578
187 Added 7.89%
2,558 $453,000
Q2 2023

Jul 13, 2023

BUY
$185.01 - $212.05 $15,540 - $17,812
84 Added 3.67%
2,371 $450,000
Q1 2023

Apr 26, 2023

SELL
$182.66 - $235.53 $33,426 - $43,101
-183 Reduced 7.41%
2,287 $458,000
Q4 2022

Jan 20, 2023

BUY
$185.53 - $241.31 $50,278 - $65,395
271 Added 12.32%
2,470 $0
Q3 2022

Oct 26, 2022

SELL
$138.54 - $232.0 $25,075 - $41,992
-181 Reduced 7.61%
2,199 $440,000
Q2 2022

Jul 18, 2022

SELL
$120.42 - $169.29 $62,257 - $87,522
-517 Reduced 17.85%
2,380 $347,000
Q1 2022

Apr 11, 2022

BUY
$127.18 - $173.91 $90,297 - $123,476
710 Added 32.46%
2,897 $473,000
Q4 2021

Jan 19, 2022

BUY
$159.56 - $209.29 $13,881 - $18,208
87 Added 4.14%
2,187 $371,000
Q3 2021

Oct 08, 2021

BUY
$169.75 - $207.73 $26,990 - $33,029
159 Added 8.19%
2,100 $397,000
Q2 2021

Jul 13, 2021

SELL
$128.63 - $176.89 $24,439 - $33,609
-190 Reduced 8.92%
1,941 $329,000
Q4 2020

Feb 11, 2021

BUY
$122.97 - $147.0 $262,049 - $313,257
2,131 New
2,131 $277,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $31.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Veriti Management LLC Portfolio

Follow Veriti Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Veriti Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Veriti Management LLC with notifications on news.